- Home
- BLRX vs HOTH Comparison
BLRX vs HOTH Comparison
Compare BLRX & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- HOTH
- Stock Information
- Founded
- BLRX 2003
- HOTH 2017
- Country
- BLRX Israel
- HOTH United States
- Employees
- BLRX N/A
- HOTH N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- BLRX Health Care
- HOTH Health Care
- Exchange
- BLRX Nasdaq
- HOTH Nasdaq
- Market Cap
- BLRX 17.1M
- HOTH 18.0M
- IPO Year
- BLRX 2011
- HOTH 2019
- Fundamental
- Price
- BLRX $3.40
- HOTH $1.17
- Analyst Decision
- BLRX Strong Buy
- HOTH Strong Buy
- Analyst Count
- BLRX 2
- HOTH 2
- Target Price
- BLRX $19.00
- HOTH $4.50
- AVG Volume (30 Days)
- BLRX 24.1K
- HOTH 316.4K
- Earning Date
- BLRX 11-24-2025
- HOTH 11-12-2025
- Dividend Yield
- BLRX N/A
- HOTH N/A
- EPS Growth
- BLRX N/A
- HOTH N/A
- EPS
- BLRX N/A
- HOTH N/A
- Revenue
- BLRX $12,735,000.00
- HOTH N/A
- Revenue This Year
- BLRX N/A
- HOTH N/A
- Revenue Next Year
- BLRX N/A
- HOTH N/A
- P/E Ratio
- BLRX N/A
- HOTH N/A
- Revenue Growth
- BLRX N/A
- HOTH N/A
- 52 Week Low
- BLRX $2.30
- HOTH $0.66
- 52 Week High
- BLRX $14.70
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- BLRX 50.28
- HOTH 39.72
- Support Level
- BLRX $3.20
- HOTH $1.14
- Resistance Level
- BLRX $3.53
- HOTH $1.22
- Average True Range (ATR)
- BLRX 0.21
- HOTH 0.08
- MACD
- BLRX 0.03
- HOTH -0.00
- Stochastic Oscillator
- BLRX 93.02
- HOTH 46.77
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).